Literature DB >> 31913578

Hypertension prevalence and control in Ulaanbaatar, Mongolia.

Harry Potts1, Uurtsaikh Baatarsuren2,3, Maral Myanganbayar2, Baigal Purevdorj2, Burtu-Ujin Lkhagvadorj2, Namuun Ganbat2, Alimaa Dorjpalam2, Delgerbat Boldbaatar2,4, Khulan Tuvdendarjaa2,3, Dulmaa Sampilnorov2,3, Khatantuul Boldbaatar2,3, Myagmartseren Dashtseren3,5, Batbold Batsukh3,6, Namkhaidorj Tserengombo3,7, Tsolmon Unurjargal3,5,8, Enkhtuya Palam9, Roberta Bosurgi10, Geoffrey So10, Norm R C Campbell11,12,13, Andreas Bungert2, Naranbaatar Dashdorj2, Naranjargal Dashdorj2,3,4.   

Abstract

This study examines the prevalence, awareness, treatment, and control of hypertension in Ulaanbaatar, Mongolia, using both the American Heart Association and conventional thresholds (130/80 and 140/90 mm Hg, respectively). In this randomized cross-sectional study, two-stage cluster sampling was used to obtain a sample of 4515 individuals aged ≥20 years. Hypertension was defined by the use of antihypertensives in the last 2 weeks or a blood pressure at or above the thresholds of 140/90 and 130/80 mm Hg. The mean age of the participants was 41.1 ± 14.0 years and 54.5% were women. Hypertension prevalence was 25.6% (using 140/90 mm Hg) and 46.5% (using 130/80 mm Hg). Prevalence increased with age and below 50 years men were consistently more likely to be hypertensive. Among hypertensive participants, the rates of awareness, treatment, and control were 69.7%, 46.8%, and 24.0% (using 140/90 mm Hg) and 49.1%, 25.8%, and 6.4% (using 130/80 mm Hg, respectively). Men had lower rates of awareness, treatment, and control compared with women, with the most pronounced differences at younger ages. This study shows that awareness, treatment, and control rates in Ulaanbaatar are better than in most low- and middle-income countries but are still suboptimal. The largest "care gap" was in young men where a regulatory requirement for annual workplace blood pressure screening has the potential to enhance care. A major hypertension control program has just been initiated in Ulaanbaatar.
© 2020 Wiley Periodicals, Inc.

Entities:  

Keywords:  hypertension awareness; hypertension control; hypertension prevalence; hypertension treatment

Mesh:

Substances:

Year:  2020        PMID: 31913578      PMCID: PMC8029771          DOI: 10.1111/jch.13784

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  19 in total

1.  Validation of the Microlife BP 3BTO-A oscillometric blood pressure monitoring device according to a modified British Hypertension Society protocol.

Authors:  Alexandra C Cuckson; Annemarie Reinders; Husain Shabeeh; Andrew H Shennan
Journal:  Blood Press Monit       Date:  2002-12       Impact factor: 1.444

2.  The variance of hypertension prevalence detected by epidemiological survey against clinical practice: data from a rural population in South China.

Authors:  Min Lai; Huiyu Tong; Yirong Wan; Wenying Wang; Hai Su
Journal:  J Am Soc Hypertens       Date:  2018-11-22

3.  Potential U.S. Population Impact of the 2017 ACC/AHA High Blood Pressure Guideline.

Authors:  Paul Muntner; Robert M Carey; Samuel Gidding; Daniel W Jones; Sandra J Taler; Jackson T Wright; Paul K Whelton
Journal:  J Am Coll Cardiol       Date:  2017-11-13       Impact factor: 24.094

4.  The state of hypertension care in 44 low-income and middle-income countries: a cross-sectional study of nationally representative individual-level data from 1·1 million adults.

Authors:  Pascal Geldsetzer; Jennifer Manne-Goehler; Maja-Emilia Marcus; Cara Ebert; Zhaxybay Zhumadilov; Chea S Wesseh; Lindiwe Tsabedze; Adil Supiyev; Lela Sturua; Silver K Bahendeka; Abla M Sibai; Sarah Quesnel-Crooks; Bolormaa Norov; Kibachio J Mwangi; Omar Mwalim; Roy Wong-McClure; Mary T Mayige; Joao S Martins; Nuno Lunet; Demetre Labadarios; Khem B Karki; Gibson B Kagaruki; Jutta M A Jorgensen; Nahla C Hwalla; Dismand Houinato; Corine Houehanou; Mohamed Msaidié; David Guwatudde; Mongal S Gurung; Gladwell Gathecha; Maria Dorobantu; Albertino Damasceno; Pascal Bovet; Brice W Bicaba; Krishna K Aryal; Glennis Andall-Brereton; Kokou Agoudavi; Andrew Stokes; Justine I Davies; Till Bärnighausen; Rifat Atun; Sebastian Vollmer; Lindsay M Jaacks
Journal:  Lancet       Date:  2019-07-18       Impact factor: 79.321

5.  Standards for the uniform reporting of hypertension in adults using population survey data: recommendations from the World Hypertension League Expert Committee.

Authors:  Marianne E Gee; Norm Campbell; Nizal Sarrafzadegan; Tazeen Jafar; Tej K Khalsa; Birinder Mangat; Neil Poulter; Dorairaj Prabhakaran; Sandor Sonkodi; Paul K Whelton; Mark Woodward; Xin-Hua Zhang
Journal:  J Clin Hypertens (Greenwich)       Date:  2014-08-26       Impact factor: 3.738

Review 6.  2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.

Authors:  Paul K Whelton; Robert M Carey; Wilbert S Aronow; Donald E Casey; Karen J Collins; Cheryl Dennison Himmelfarb; Sondra M DePalma; Samuel Gidding; Kenneth A Jamerson; Daniel W Jones; Eric J MacLaughlin; Paul Muntner; Bruce Ovbiagele; Sidney C Smith; Crystal C Spencer; Randall S Stafford; Sandra J Taler; Randal J Thomas; Kim A Williams; Jeff D Williamson; Jackson T Wright
Journal:  Hypertension       Date:  2017-11-13       Impact factor: 9.897

7.  The H-ATOMIC Criteria for the Etiologic Classification of Patients with Intracerebral Hemorrhage.

Authors:  Joan Martí-Fàbregas; Luis Prats-Sánchez; Alejandro Martínez-Domeño; Pol Camps-Renom; Rebeca Marín; Elena Jiménez-Xarrié; Blanca Fuentes; Laura Dorado; Francisco Purroy; Susana Arias-Rivas; Raquel Delgado-Mederos
Journal:  PLoS One       Date:  2016-06-08       Impact factor: 3.240

8.  Blood Pressure Control and Cardiovascular Outcomes: Real-world Implications of the 2017 ACC/AHA Hypertension Guideline.

Authors:  Ji Hyun Lee; Sun-Hwa Kim; Si-Hyuck Kang; Jun Hwan Cho; Youngjin Cho; Il-Young Oh; Chang-Hwan Yoon; Hae-Young Lee; Tae-Jin Youn; In-Ho Chae; Cheol-Ho Kim
Journal:  Sci Rep       Date:  2018-09-03       Impact factor: 4.379

9.  Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016.

Authors: 
Journal:  Lancet       Date:  2017-09-16       Impact factor: 79.321

10.  Impact of 2017 ACC/AHA guidelines on prevalence of hypertension and eligibility for antihypertensive treatment in United States and China: nationally representative cross sectional study.

Authors:  Rohan Khera; Yuan Lu; Jiapeng Lu; Anshul Saxena; Khurram Nasir; Lixin Jiang; Harlan M Krumholz
Journal:  BMJ       Date:  2018-07-11
View more
  3 in total

1.  Hypertension prevalence and control in Ulaanbaatar, Mongolia.

Authors:  Harry Potts; Uurtsaikh Baatarsuren; Maral Myanganbayar; Baigal Purevdorj; Burtu-Ujin Lkhagvadorj; Namuun Ganbat; Alimaa Dorjpalam; Delgerbat Boldbaatar; Khulan Tuvdendarjaa; Dulmaa Sampilnorov; Khatantuul Boldbaatar; Myagmartseren Dashtseren; Batbold Batsukh; Namkhaidorj Tserengombo; Tsolmon Unurjargal; Enkhtuya Palam; Roberta Bosurgi; Geoffrey So; Norm R C Campbell; Andreas Bungert; Naranbaatar Dashdorj; Naranjargal Dashdorj
Journal:  J Clin Hypertens (Greenwich)       Date:  2020-01-08       Impact factor: 3.738

2.  National trends in prevalence, awareness, treatment, and control of hypertension among adults in Mongolia from 4 cross-sectional surveys in 2005, 2009, 2013, and 2019.

Authors:  Supa Pengpid; Karl Peltzer
Journal:  Medicine (Baltimore)       Date:  2022-08-19       Impact factor: 1.817

3.  Risk Factors for Cerebral Aneurysm Rupture in Mongolia.

Authors:  Matthias Bechstein; Amarjargal Gansukh; Boldbat Regzengombo; Oyun Byambajav; Lukas Meyer; Michael Schönfeld; Helge Kniep; Uta Hanning; Gabriel Broocks; Tserenchunt Gansukh; Jens Fiehler
Journal:  Clin Neuroradiol       Date:  2021-06-30       Impact factor: 3.156

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.